Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients

Abstract

Validation of these findings may enable proteomic profiling to become a valuable tool for identifying high-risk melanoma patients eligible for adjuvant therapeutic interventions.

Human body fluid proteome analysis

“…Plasma/serum peptidome is often prepared from the whole proteome using physical methods such as centrifugal ultrafiltration, gel chromatography, or precipitation, and during the sample preparation, some artificial occurring processes (e.g., cell lysis, proteolysis) should be minimized. Analysis and profiling of plasma/serum peptidome has been performed with 2-D LC-MS/MS, FT-ICR-MS, MALDI-TOF-MS, SELDI-TOF-MS, or LC-MS [13,[58][59][60][61][62][63][64]. Magnetic beads/particles are very useful for enrichment of serum peptides and can greatly enhance the reproducibility of MALDI-TOF-MS analysis of the peptides [59,60].…”

Biomarkers for Melanoma Diagnosis and the Technologies Used to Identify Them

“…It has been suggested that GPC3 may be a useful early stage biomarker for patients with the early stages of the disease (0 -II) (Nakatsura et al, 2004;Ikuta et al, 2005). Moreover, cyclooxygenase-2 (COX-2) (Chwirot and Kuźbicki, 2007), serum amyloid A (SAA) (Mian et al, 2005;Findeisen et al, 2009) and DNA methylation profiling (Conway et al, 2011) can be used to distinguish between early melanomas and benign nevi.…”

“…The traditional serological biomarkers of melanoma such as LDH, S100B and CRP lack sensitivity as early stage melanoma biomarkers. To search for early stage biomarkers, Findeisen et al extensively analyzed the serum proteome of about 600 melanoma patients at each stage of the disease (stages I -IV) by SELDI-TOF-MS technique (Mian et al, 2005;Findeisen et al, 2009). This analysis led to the discovery of a new biomarker, SAA, which was found to be highly sensitive for detecting early stage melanoma.…”

Identification of serum melanoma progression biomarkers through proteomic-based approaches

“…Schadendorf and coworkers added new data to the field of melanoma protein profiling. Based on a SELDI-TOF mass spectrometry (MS) assay and artificial ana lysis network, the authors demonstrated that 80% of stage III serum samples could be correctly identified as promoting progression using random sample cross-validation statistical methodology, compared with a 21% prediction rate when they used S100B as a marker [8]. Interestingly, the use of an F score for testing equality of variances between two independent populations (stage I vs stage IV melanoma serum samples) revealed that one region with mass values centered at approximately 11,700 Da was noted to be significantly different in variance between the two populations.…”